Acadia Pharmaceuticals (ACAD) FY2020 results: revenue $442 million, up 30.3% on the year
Acadia Pharmaceuticals Inc. (ACAD) reported revenue of $442 million for fiscal 2020, the year ended 31 December 2020, up 30.3% on the year before. Net income was -$282 million, and diluted earnings per share $-1.79. The figures are the company's own, from the 10-K it filed with the SEC on 25 February 2021.
Revenue
$442 million
+30.3% on the year
FY2013FY2020
Operating margin
-64.9%
-72.7% a year earlier
FY2013FY2020
Net income
-$282 million
FY2013FY2020
Diluted EPS
-$1.79
FY2013FY2020
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Revenue
442
339
224
+30.3%
Cost of revenue
10.2
11.3
12.4
-10.0%
Gross profit
432
328
211
+31.7%
Gross margin
97.7%
96.7%
94.5%
Research and development
319
240
187
+32.8%
Selling, general and administrative
389
326
266
+19.4%
Operating income
-287
-247
-247
Operating margin
-64.9%
-72.7%
-110.6%
Pre-tax income
-281
-234
-244
Income tax
0.6
0.9
1.3
-30.3%
Net income
-282
-235
-245
Net margin
-63.7%
-69.4%
-109.6%
Diluted EPS
-$1.79
-$1.60
-$1.94
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Operating cash flow
-136
-151
-167
Capital expenditure
7.6
1.1
2.1
+572.0%
Free cash flow
-144
-152
-170
Free cash flow margin
-32.5%
-44.9%
-75.8%
Cash from investing
193
-166
-71.5
Cash from financing
81.0
372
307
-78.2%
Depreciation and amortisation
2.9
2.8
3.0
+6.0%
Share-based compensation
84.4
82.3
81.6
+2.6%
Diluted shares, weighted
157m
n/a
n/a
Shares outstanding at period end
160m
155m
144m
+2.8%
Balance sheet
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Shareholders' equity
627
699
479
-10.3%
Debt
0.0
0.0
n/a
Operating lease liabilities
44.5
6.4
n/a
+598.9%
Other liabilities
111
77.7
61.1
+43.1%
Total liabilities and equity
783
783
540
-0.1%
Fixed assets
9.2
3.2
3.3
+188.1%
Intangible assets
1.1
2.6
4.1
-57.1%
Investments
306
508
339
-39.7%
Cash and equivalents
326
190
135
+71.9%
Receivables
48.2
35.8
26.1
+34.8%
Inventory
9.7
6.3
4.1
+52.7%
Other assets
82.5
37.9
29.2
+117.8%
Total assets
783
783
540
-0.1%
10-K for the year ended 31 December 2020, filed 25 February 2021: the filing.